MAPT and Alzheimer disease: The evidence thus far highlights that tau, rather than amyloid-beta (Aβ) alone, is a reliable indicator of future clinical progression,11,18 and is well associated with cognitive change in the early stages of Alzheimer’s disease.19-23 Therefore, if tau patterns and their progression are indeed heterogeneous, it is likely that tracking tau with a single set of regions across participants may misrepresent a significant portion of them.